Valuation: PharmaEssentia Corporation

Market Cap 493B 15.2B 13.28B 12.26B 11.3B 21.3B 1,464B 21.77B 147B 57.63B 717B 57.09B 55.84B 2,468B P/E 2026 *
45.9x
P/E 2027 * 33.4x
Enterprise Value 466B 14.38B 12.57B 11.6B 10.69B 20.15B 1,385B 20.6B 139B 54.53B 678B 54.02B 52.83B 2,335B EV / Sales 2026 *
18.6x
EV / Sales 2027 * 13.2x
Free-Float
75.37%
Yield 2026 *
0.08%
Yield 2027 * 0.12%
1 week+11.00%
Current month+11.00%
1 month+11.00%
3 months+11.00%
6 months+11.00%
Current year 13.96
Extreme 13.964
15.5
1 year 13.96
Extreme 13.964
15.5
3 years 13.96
Extreme 13.964
15.5
5 years 13.96
Extreme 13.964
15.5
10 years 13.96
Extreme 13.964
15.5
Manager TitleAgeSince
Chief Executive Officer - 01/01/2003
Director of Finance/CFO - 14/10/2015
Chief Tech/Sci/R&D Officer - 01/08/2022
Director TitleAgeSince
Chairman - 01/09/2003
Director/Board Member - -
Director/Board Member - 30/06/2009
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+11.00% - - 16.09B
-7.17%-2.63%+49.59%+74.24% 55.98B
+0.24%-1.54%+53.22%+71.85% 53.69B
+1.05%-5.89%+4.44%+425.60% 23.29B
+0.45%+0.28%-17.38%-14.42% 23.15B
-5.95%-0.22%+35.96%-9.58% 20.58B
-1.14%+0.03%+31.57%-30.42% 17.76B
-6.91%+2.40%+36.86%+636.97% 15.93B
+0.31%-1.55%+23.97%+189.86% 14B
-0.21%+1.53%+56.25%+144.31% 12.58B
Average -1.95%-1.05%+30.50%+165.38% 26.33B
Weighted average by Cap. -2.40%-2.07%+34.88%+132.82%

Financials

2026 *2027 *
Net sales 25.07B 774M 676M 624M 575M 1.08B 74.49B 1.11B 7.46B 2.93B 36.48B 2.91B 2.84B 126B 34.57B 1.07B 932M 860M 793M 1.49B 103B 1.53B 10.28B 4.04B 50.31B 4.01B 3.92B 173B
Net income 10.85B 335M 293M 270M 249M 469M 32.26B 480M 3.23B 1.27B 15.8B 1.26B 1.23B 54.38B 14.97B 462M 404M 373M 343M 647M 44.49B 662M 4.45B 1.75B 21.79B 1.74B 1.7B 75.01B
Net Debt -26.52B -818M -715M -660M -608M -1.15B -78.82B -1.17B -7.89B -3.1B -38.6B -3.07B -3.01B -133B -34.73B -1.07B -937M -864M -797M -1.5B -103B -1.53B -10.33B -4.06B -50.54B -4.02B -3.94B -174B
Logo PharmaEssentia Corporation
PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the research and development of new drugs, which are used for treatment of hematology, such as meloproliferative neoplasms (MPN), neutropenia, anemia; infectious disease, such as hepatitis C and hepatitis B; dermatology, such as psoriasis, and neurology, such as multiple sclerosis, among others. The Company’s products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, PEG-EPO and others. The Company distributes its products within domestic market and to overseas markets.
Employees
131
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1,195.00TWD
Average target price
1,073.31TWD
Spread / Average Target
-10.18%

Quarterly revenue - Rate of surprise